CLSA, various

California Life Sciences Association (CLSA) announced the appointment of nine executives, coming from leadership teams of top pharmaceutical and biotechnology companies, including Amgen, DuPont and Boehringer Ingelheim, as members of its board of directors:

• Victoria Blatter, SVP, US government affairs, Amgen
• Elizabeth Grammer, EVP, general counsel and head of human resources, Ardelyx
• Jennifer Johnson, associate general counsel, DuPont Nutrition & Biosciences
• Casey Lynch, CEO, co-founder and chairman, Cortexyme
• Joshua Ofman, chief of corporate strategy and external affairs, GRAIL
• Matthew Plunkett, SVP and CFO, Nkarta Therapeutics
• Stacey Pugh, VP and general manager, neurovascular, Medtronic
• Fran Schulz, partner, assurance services – Life Sciences Practice, Ernst & Young
• Bridget Walsh, VP, government affairs and public policy, Boehringer Ingelheim

The association’s CEO, Mike Guerra welcomed the new members, saying that California’s life sciences sector is currently going through a period of ‘strong growth’, which the ‘diverse’ group of executives added to the board are expected to help sustain.